Magenta Therapeutics (MGTA) Receives a Hold from H.C. Wainwright
TipRanks · 5d ago
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Benzinga · 02/28 15:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agenus (AGEN), EyePoint Pharmaceuticals (EYPT) and Magenta Therapeutics (MGTA)
TipRanks · 02/28 11:20
HC Wainwright & Co. Initiates Coverage On Magenta Therapeutics with Neutral Rating
Benzinga · 02/28 11:05
--HC Wainwright Initiates Magenta Therapeutics at Neutral
--HC Wainwright Initiates Magenta Therapeutics at Neutral
MT Newswires · 02/28 09:42
Gilder Gagnon Howe & Co Now Owns 0.70% of Magenta Therapeutics (MGTA)
NASDAQ · 02/14 11:56
Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms
Benzinga · 02/09 15:13
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Benzinga · 02/08 12:17
BRIEF-Magenta Therapeutics Inc Says As Of Dec 31, 2022, Co's Cash, Cash Equivalents, Marketable Securities Were About $112 Mln
Reuters · 02/07 21:57
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 02/03 17:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 02/03 13:06
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
MT Newswires · 02/03 09:18
BRIEF-Magenta Therapeutics Inc Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement
Reuters · 02/02 22:16
Magenta Therapeutics up 47% on plan to pursue strategic alternatives
Seeking Alpha · 02/02 22:06
Magenta Therapeutics To Explore Strategic Alternatives; Co. Has Made The Determination To Halt Further Development Of Its Programs And Conduct A Comprehensive Review Of Strategic Alternatives Focused On Maximizing Shareholder Value
Benzinga · 02/02 21:38
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 02/02 21:31
Magenta cut to Neutral at Wedbush as leukemia trial comes to a halt
Seeking Alpha · 01/26 19:59
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 01/26 18:28
BTIG Downgrades Magenta Therapeutics to Neutral
Benzinga · 01/26 15:38
Cowen & Co. Downgrades Magenta Therapeutics to Market Perform
Benzinga · 01/26 13:10
Webull provides a variety of real-time MGTA stock news. You can receive the latest news about Magenta Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MGTA
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The Company's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. It is developing product candidates to be used individually or, in some cases, in combination with each other.